Q-omics provides the consensus-scored GAB3 profile across patient tissues and cancer cell-line models. GAB3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GAB3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GAB3 RNA expression shows 20,757 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where GAB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAB3 survival associations across molecular data types. GAB3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAB3 RNA expression–survival associations across cancer types. High GAB3 expression shows unfavorable associations in UVM, but favorable associations in SKCM, HNSC, LUAD, SCLC and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GAB3 RNA expression.
This table summarizes GAB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GAB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAB3 shows lower tumor expression in LUAD, LUSC, BLCA, COAD and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher GAB3 RNA expression in tumor versus normal tissue (log2 FC = +1.190, t-test p < 0.001).
This table shows molecular features associated with GAB3 in patient tissues and cancer cell lines. In patient samples, GAB3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GAB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
